Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia-Reference-Cited by-同舟云学术

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia

Published:2021-11 Issue:48 Volume:39 Page:7052-7057
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Gordon Sally F.,Clothier Hazel J.,Morgan Hannah,Buttery Jim P.,Phuong Linny K.,Monagle Paul,Chunilal Sanjeev,Wood Erica M.,Tran Huyen,Szer Jeff,Crawford Nigel W.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. Operation COVID Shield. National COVID Vaccine Campaign Plan, https://www.health.gov.au/sites/default/files/documents/2021/08/op-covid-shield-national-covid-vaccine-campaign-plan.pdf.; 2021 [accessed 13 August 2021].

2. Therapeutic Goods Administration (TGA). Australian Product Information: COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection, https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-01194-1&d=20210814172310101; 2021 [accessed 13 August 2021].

3. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination;Greinacher;N Engl J Med,2021

4. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination;Schultz;N Engl J Med,2021

5. Brighton Collaboration. Priority list of Adverse Events of Special Interest: COVID-19, https://brightoncollaboration.us/priority-list-aesi-covid/; 2020 [accessed 13 August 2021].

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID‐19‐induced immune thrombocytopenia management approach: A case report and literature review;Clinical Case Reports;2024-06

2. Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 –nCov-19): A Case Report With OneYear Follow-Up;Hospital Pharmacy;2024-04-27

3. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals;Vaccine;2024-04

4. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety;Vaccine;2024-02

5. Safety of Immunization for Children with Immune Thrombocytopenia;Vaccines;2024-01-09